Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi’i A. A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. computers in biology and medicine. 2021;136. https://www.sciencedirect.com/science/article/pii/S0010482521005485.

PAHO. World Obesity Day 2022: accelerating action to end obesity - PAHO/WHO | Pan American Health Organization. Pan American Health Organization; 2022 https://www.paho.org/pt/noticias/4-3-2022-dia-mundial-da-obesidade-2022-acelerar-acao-para-acabar-com-obesidade#:~:text=4%20de%20mar%C3%A7o%20de%202022.

ABESO. Obesity map. Obesity and metabolic syndrome. Brazilian Association for the Study of Obesity and Metabolic Syndrome; 2023. https://abeso.org.br/obesidade-e-sindrome-metabolica/mapa-da-obesidade/.

Haslam DW, James WPT. Obesity. Lancet. 2005;366:1197–209.

Article  PubMed  Google Scholar 

Gonzalo-Encabo P, Maldonado G, Valadés D, Ferragut C, Pérez-López A. The role of exercise training on low-grade systemic inflammation in adults with overweight and obesity: a systematic review. Int J Environ Res Public Health. 2021;18:13258.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jakicic JM, Davis KK. Obesity and physical activity. Psychiatr Clin N Am. 2011;34:829–40. https://www.sciencedirect.com/science/article/abs/pii/S0193953X11000864?via%3Dihub.

Article  Google Scholar 

Aaseth J, Ellefsen S, Alehagen U, Sundfør TM, Alexander J. Diets and drugs for weight loss and health in obesity (an update). Biomed Pharmacother. 2021;140:111789.

Article  CAS  PubMed  Google Scholar 

Smith BR, Schauer P, Nguyen NT. Surgical approaches to the treatment of obesity: bariatric surgery. Endocrinol Metab Clin N Am. 2008;37:943–64.

Article  Google Scholar 

Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. Pharm Ther. 2017;3:180–8.

Google Scholar 

Lian J, Casari I, Falasca M. Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract. Pharmacol Res. 2022;175:106025 https://www.sciencedirect.com/science/article/pii/S1043661821006095.

Article  CAS  PubMed  Google Scholar 

de Souza TM. Vias metabólicas, Potencial Prático E Antagonismo Do Sistema canabinóide: Uma Revisão bibliográfica. [Monografia (Especialização) - Curso De Medicina]. Universidade Federal da Bahia (UFBA); 2012. p. 1–51.

Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55:3053–60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228260/.

Article  PubMed  Google Scholar 

Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–43. https://www.ncbi.nlm.nih.gov/pubmed/16186383.

Article  CAS  PubMed  Google Scholar 

You T, Disanzo BL, Wang X, Yang R, Gong D. Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise. Lipids Health Dis. 2011;10:194.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes-Justo E, Garfias-Ramirez SH, Flores A. The function of the endocannabinoid system in the pancreatic islet and its implications on metabolic syndrome and diabetes. Islets. 2023;15:1–11.

Article  PubMed  PubMed Central  Google Scholar 

Barré T, Bourlière M, Ramier C, Carrat F, Di Beo V, Protopopescu C, et al. Cannabis use is inversely associated with metabolic disorders in hepatitis c-infected patients (ANRS CO22 Hepather Cohort). J Clin Med. 2022;11:6135. https://www.mdpi.com/2077-0383/11/20/6135.

Article  PubMed  PubMed Central  Google Scholar 

Abuhasira R, Azar S, Nemirovski A, Tam J, Novack V. Herbal cannabis use is not associated with changes in levels of endocannabinoids and metabolic profile alterations among older adults. Life. 2022;12:1539.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kowalczuk A, Marycz K, Kornicka J, Groborz S, Meissner JM, Mularczyk M. Tetrahydrocannabivarin (THCV) protects adipose-derived mesenchymal stem cells (ASC) against endoplasmic reticulum stress development and reduces inflammation during adipogenesis. Int J Mol Sci. 2023;24:7120–0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions. Vol 6.4. Cochrane; 2023. www.training.cochrane.org/handbook.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71.

Article  Google Scholar 

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. systematic reviews. 2016;5. https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-016-0384-4.

Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth 2023;21:494–506.

Article  PubMed  Google Scholar 

Khan Academy. Diferencias De Medias muestrales: Ejemplos De Probabilidad (artículo). Khan Academy; 2023. https://es.khanacademy.org/math/ap-statistics/sampling-distribution-ap/xfb5d8e68:sampling-distribution-diff-means/a/diff-sample-means-probability-examples.

Borenstein M. Introduction to meta-analysis. Wiley, Chicester; 2009. https://www.wiley.com/en-us/Introduction+to+Meta+Analysis-p-9780470057247.

Cochrane. How to do a cochrane systematic review. 2020. https://brazil.cochrane.org/como-fazer-uma-revis%C3%A3o-sistem%C3%A1tica-cochrane.

Deeks J, Higgins J, Altman D. Chapter 10: analysing data and undertaking meta-analyses. 2019. https://training.cochrane.org/handbook/current/chapter-10.

Lopez HL, Cesareo KR, Raub B, Kedia AW, Sandrock JE, Kerksick CM, et al. Effects of hemp extract on markers of wellness, stress resilience, recovery and clinical biomarkers of safety in overweight, but otherwise healthy subjects. J Diet Suppl. 2020;17:561–86. https://pubmed.ncbi.nlm.nih.gov/32456572/.

Article  CAS  PubMed  Google Scholar 

O’Leary DH, Reuwer AQ, Nissen SE, Despres JP, Deanfield JE, Brown MW, et al. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR trial. Heart. 2011;97:1143–50.

Article  PubMed  Google Scholar 

Bergholm R, Sevastianova K, Santos A, Kotronen A, Urjansson M, Hakkarainen A, et al. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans. Int J Obes. 2013;37:699–703.

Article  CAS  Google Scholar 

Hollander PA, Amod A, Litwak LE, Chaudhari U. Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. Diabetes Care. 2010;33:605–7.

Article  CAS  PubMed  Google Scholar 

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–97.

Article  PubMed  Google Scholar 

Scheen AJ, Finer N, Hollander P, Jensen MD, Van, Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660–72.

Article  CAS  PubMed  Google Scholar 

Pataky Z, Gasteyger C, Ziegler O, Rissanen A, Hanotin C, Golay A. Efficacy of rimonabant in obese patients with binge eating disorder. Exp Clin Endocrinol Diabetes. 2012;121:20–6.

Article  PubMed  Google Scholar 

Backhouse K, Šarac I, Shojaee‐Moradie F, Stolinski M, Robertson MD, Frost G, et al. Fatty acid flux and oxidation are increased by rimonabant in obese women. Metabolism. 2012;61:1220–3.

Article  CAS  PubMed  Google Scholar 

Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe study. Eur Heart J. 2008;29:1761–71.

Article  PubMed  Google Scholar 

Alizadeh S, Djafarian K, Mofidi Nejad M, Yekaninejad MS, Javanbakht MH. The effect of β-caryophyllene on food addiction and its related behaviors: a randomized, double-blind, placebo-controlled trial. Appetite. 2022;178:106160.

Article  PubMed  Google Scholar 

Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39:1777–86. https://care.diabetesjournals.org/content/39/10/1777.

Article  CAS  PubMed  Google Scholar 

Carley DW, Prasad B, Reid KJ, Malkani R, Attarian H, Abbott SM, et al. Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea. Sleep. 2018;41:zsx184.

Article  PubMed  Google Scholar 

Cavalheiro EKFF, Costa AB, Salla DH, da Silva MR, Mendes TF, da Silva LE, et al. Cannabis Sativa as a treatment for obesity: from anti-inflammatory indirect support to a promising metabolic re-establishment target. Cannabis Cannabinoid Res. 2021;7:135–51.

Article  PubMed  Google Scholar 

Miralpeix C, Reguera AC, Fosch A, Zagmutt S, Casals N, Cota D, et al. Hypothalamic endocannabinoids in obesity: an old story with new challenges. Cell Mol Life Sci. 2021;78:7469–90. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557709/.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, et al. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism? or inverse agonism ? as potential obesity treatment and other therapeutic use. J Clin Pharm Ther. 2007;32:209–31.

Article  CAS  PubMed  Google Scholar 

Kirkham T, Tucci S. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets. 2006;5:275–92.

Article  CAS  Google Scholar 

Nuesch E, Trelle S, Reichenbach S, Rutjes AWS, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ. 2010;341:c3515–5.

Article  PubMed  PubMed C